Novavax’s prototype vaccine effective against omicron variants, study finds

In a late-stage trial, Novavax’s prototype COVID-19 vaccine increased neutralizing antibody titers up to 34 times higher than primary vaccination among adults, with a “significant boost” against omicron variants and subvariants BA.1, BA.2 and BA.5. 

Advertisement

In the same study, one booster shot increased neutralizing titers 2.7-fold among teenagers between 12 and 17 years old, Novavax said Oct. 12. 

The vaccine-maker, which began distributing its COVID-19 vaccine after gaining the FDA and CDC’s authorization in July, said the prototype booster doses were well tolerated and side effects were mainly mild to moderate.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.